Targeting transcription factors for cancer treatment

M Lambert, S Jambon, S Depauw… - Molecules, 2018 - mdpi.com
Transcription factors are involved in a large number of human diseases such as cancers for
which they account for about 20% of all oncogenes identified so far. For long time, with the …

Cancer therapeutics using survivin BIRC5 as a target: what can we do after over two decades of study?

F Li, I Aljahdali, X Ling - Journal of Experimental & Clinical Cancer …, 2019 - Springer
Survivin (also named BIRC5) is a well-known cancer therapeutic target. Since its discovery
more than two decades ago, the use of survivin as a target for cancer therapeutics has …

Camptothecin (CPT) and its derivatives are known to target topoisomerase I (Top1) as their mechanism of action: did we miss something in CPT analogue molecular …

F Li, T Jiang, Q Li, X Ling - American journal of cancer …, 2017 - pmc.ncbi.nlm.nih.gov
Camptothecin (CPT) was discovered from plant extracts more than 60 years ago. Since then,
only two CPT analogues (irinotecan and topotecan) have been approved for cancer …

Hemicellulose from plant biomass in medical and pharmaceutical application: A critical review

X Liu, Q Lin, Y Yan, F Peng, R Sun… - Current Medicinal …, 2019 - ingentaconnect.com
Background: Due to the non-toxicity, abundance and biodegradability, recently more and
more attention has been focused on the exploration of hemicellulose as the potential …

A novel small molecule FL118 that selectively inhibits survivin, Mcl-1, XIAP and cIAP2 in a p53-independent manner, shows superior antitumor activity

X Ling, S Cao, Q Cheng, JT Keefe, YM Rustum, F Li - 2012 - journals.plos.org
Drug/radiation resistance to treatment and tumor relapse are major obstacles in identifying a
cure for cancer. Development of novel agents that address these challenges would therefore …

Suppression of survivin promoter activity by YM155 involves disruption of Sp1-DNA interaction in the survivin core promoter

Q Cheng, X Ling, A Haller, T Nakahara… - … of biochemistry and …, 2012 - pmc.ncbi.nlm.nih.gov
YM155, a novel survivin suppressant, shows potent antitumor activity against various human
cancers and is currently in phase II clinical trials. In this study, we investigated whether …

Targeting transcription factor binding to DNA by competing with DNA binders as an approach for controlling gene expression

M Amine Bouhlel, M Lambert… - Current topics in …, 2015 - ingentaconnect.com
Transcription factors are recognized as the master regulators of gene expression.
Interestingly, about 10% of the transcription factors described in mammals are up to date …

Macrocarpal I induces immunogenic cell death and synergizes with immune checkpoint inhibition by targeting tubulin and PARP1 in colorectal cancer

Y Zhang, H Li, Y Zhao, L Liu, Y Zhou, X Pan… - Cell Death …, 2025 - nature.com
Colorectal cancer (CRC) presents an obstacle to immunotherapy, primarily because most
cases are microsatellite stable (MSS) tumors, which are often described as “cold tumors” …

A cell-permeable dominant-negative survivin protein induces apoptosis and sensitizes prostate cancer cells to TNF-α therapy

CHA Cheung, X Sun, JR Kanwar, JZ Bai… - Cancer cell …, 2010 - Springer
Background Survivin is a member of the inhibitor-of-apoptosis (IAP) family which is widely
expressed by many different cancers. Overexpression of survivin is associated with drug …

Chemotherapeutic efficacies of a clofazimine and diminazene aceturate combination against piroplasm parasites and their AT-rich DNA-binding activity on Babesia …

B Tuvshintulga, M AbouLaila, T Sivakumar… - Scientific Reports, 2017 - nature.com
Recently, we reported that clofazimine (CF) has an anti-piroplasm activity, but it could not
completely eliminate parasites in the host. The currently available anti-piroplasm drug …